Biolife Solutions 

$24.07
+$0.67+2.86% Friday 20:00

統計

當日最高
24.33
當日最低
23.61
52週最高
26.73
52週最低
9.92
成交量
201,936
平均成交量
315,329
市值
1.19B
市盈率
-
股息收益率
-
股息
-

即將到來

收益

12Nov預期
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
下一個
-0.38
-0.28
-0.18
-0.08
預期每股收益
-0.08
實際每股收益
N/A

人們還關注

此列表基於在 Stock Events 上關注 BLFS 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

分析師評級

27.6$平均價格目標
最高估價為 $30。
來自過去 6 個月內的 5 個評級。這不是投資建議。
買入
100%
持有
0%
賣出
0%

關於

Health Technology
Medical Specialties
Manufacturing
Surgical and Medical Instrument Manufacturing
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
Show more...
首席執行官
Michael Rice
員工
409
國家
US
ISIN
US09062W2044

上市公司